NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR USE IN DOWN SYNDROME AND ALZHEIMER`S DISEASE THERAPY

The present invention relates to nucleoside reverse transcriptase inhibitors (NRTI) or their pharmaceutically acceptable salts for use in (a) the treatment of Down syndrome or the consequences thereof or (b) the prevention, inhibition of progression or treatment of Alzheimer`s disease or the consequ...

Full description

Saved in:
Bibliographic Details
Main Authors CLOTET SALA, Bonaventura, DIERSSEN SOTOS, María del Mar, PAREDES DEIRÓS, Roger, MARTÍNEZ DE LAGRÁN CABREDO, María, ELIZALDE-TORRENT, Aleix
Format Patent
LanguageEnglish
French
Published 15.06.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to nucleoside reverse transcriptase inhibitors (NRTI) or their pharmaceutically acceptable salts for use in (a) the treatment of Down syndrome or the consequences thereof or (b) the prevention, inhibition of progression or treatment of Alzheimer`s disease or the consequences thereof. Pharmaceutical compositions comprising such NRTI and combinations of NRTI are provided. Kits including NRTI, combinations of NRTI, and pharmaceutical compositions comprising such NRTI and combinations of NRTI are also described. La présente invention concerne des inhibiteurs nucléosidiques de la transcriptase inverse (NRTI) ou leurs sels pharmaceutiquement acceptables pour une utilisation dans (a) le traitement du syndrome de Down ou des conséquences de celui-ci ou (b) la prévention, l'inhibition de la progression ou le traitement de la maladie d'Alzheimer ou des conséquences de celle-ci. L'Invention concerne également des compositions pharmaceutiques comprenant de tels NRTI et des combinaisons de NRTI. L'Invention concerne également des kits comprenant NRTI, des combinaisons de NRTI, ainsi que des compositions pharmaceutiques comprenant de tels NRTI et des combinaisons de NRTI.
Bibliography:Application Number: WO2022IB00673